R. Lock

Autoregulation of 5-fluorouracil metabolism.

J. Sludden, H. McLeod, J. Cassidy, 1998, European journal of cancer.

Emerging therapies for respiratory diseases.

A. Ratcliffe, R. Lock, S. Collingwood, 2007, Drug news & perspectives.

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)

G. Dukes, V. Kupčová, M. Rosario, 2022, Journal of clinical pharmacology.

Challenges in inhaled product development and opportunities for open innovation.

Mark Gumbleton, Ben Forbes, Lea Ann Dailey, 2011, Advanced drug delivery reviews.

Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

J. Clancy, D. Renard, H. Danahay, 2013, Chest.

P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

G. D'Haens, W. Sandborn, B. Feagan, 2019, Journal of Crohn's and Colitis.

NVP‐QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia

Paul J. Groot-Kormelink, H. Danahay, P. Groot-Kormelink, 2015, British journal of pharmacology.

Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

C. Almansa, M. Cwik, S. Balani, 2022, Clinical pharmacology in drug development.